Evaluation for clinical utilization of anti-inflammatory agents in spinal cord ischemia.

我们研究了抗肿瘤坏死因子-α制剂英夫利昔单抗是否能减轻兔脊髓缺血性损伤。我们将兔分为三组(n=5，除大剂量英夫利昔单抗组外)：对照组，小剂量英夫利昔单抗组(5 mg/kg)，大剂量英夫利昔单抗组(10 mg/kg)。阻断腹主动脉15min造成脊髓缺血。再灌注后每日评定后肢运动功能(评分4分，正常至0分，截瘫)，连续7d，计数脊髓前部正常神经元数目。在神经学评分方面，组间没有显著差异。而低剂量英夫利昔单抗组的正常神经元数量明显多于对照组。提示小剂量英夫利昔单抗(5 mg/kg)对脊髓缺血性损伤有保护作用，但临床应用应慎重。

We investigated whether the ischemic spinal cord injury in rabbits was reduced by infliximab, an anti- tumor necrosis factor-alpha agent. We assigned rabbits to three groups (n=5, expect high dose infliximab group); a control group, low dose infliximab group (5mg/kg), high dose infliximab group (10mg/kg). Spinal cord ischemia was produced by occluding the abdominal aorta for 15 min. After the reperfusion, hindlimb motor function (score range: 4, normal to 0, paraplegia) was assessed daily for 7 days, and then the number of normal neurons in the anterior spinal cord was counted. There were no significant intergroup differences in neurological scores. On the other hand, the numbers of normal neurons of low dose infliximab group had significantly more than a control group. This results indicate that low dose infliximab(5mg/kg) may protect ischemic spinal cord injury, but clinical utilization of infliximab for spinal cord ischemia should be discreet.